vs
CervoMed Inc.（CRVO）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
CervoMed Inc.的季度营收约是Arcadia Biosciences, Inc.的2.0倍（$1.8M vs $901.0K），Arcadia Biosciences, Inc.净利率更高（-148.3% vs -356.1%，领先207.8%），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -46.6%），过去两年CervoMed Inc.的营收复合增速更高（7.3% vs -4.5%）
CervoMed Inc.是一家处于临床阶段的生物制药公司，专注于开发阿尔茨海默病及其他类型痴呆等神经退行性疾病的新型疗法，业务覆盖全球生物制药市场，核心研发板块致力于满足进行性脑部疾病患者未被满足的医疗需求。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
CRVO vs RKDA — 直观对比
营收规模更大
CRVO
是对方的2.0倍
$901.0K
营收增速更快
RKDA
高出20.7%
-46.6%
净利率更高
RKDA
高出207.8%
-356.1%
两年增速更快
CRVO
近两年复合增速
-4.5%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8M | $901.0K |
| 净利润 | $-6.3M | $-1.3M |
| 毛利率 | — | 21.4% |
| 营业利润率 | -376.4% | -152.8% |
| 净利率 | -356.1% | -148.3% |
| 营收同比 | -46.6% | -25.8% |
| 净利润同比 | -170.1% | 67.1% |
| 每股收益（稀释后） | — | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRVORKDA
| Q4 25 | — | $901.0K | ||
| Q3 25 | — | $1.3M | ||
| Q2 25 | $1.8M | $1.5M | ||
| Q1 25 | $1.9M | $1.2M | ||
| Q4 24 | $2.2M | $1.2M | ||
| Q3 24 | $1.9M | $1.5M | ||
| Q2 24 | $3.3M | $1.3M | ||
| Q1 24 | $2.3M | $987.0K |
净利润CRVORKDA
| Q4 25 | — | $-1.3M | ||
| Q3 25 | — | $856.0K | ||
| Q2 25 | $-6.3M | $-4.5M | ||
| Q1 25 | $-4.9M | $2.6M | ||
| Q4 24 | $-6.7M | $-4.1M | ||
| Q3 24 | $-4.8M | $-1.6M | ||
| Q2 24 | $-2.3M | $1.1M | ||
| Q1 24 | $-2.5M | $-2.4M |
毛利率CRVORKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率CRVORKDA
| Q4 25 | — | -152.8% | ||
| Q3 25 | — | -88.5% | ||
| Q2 25 | -376.4% | -34.4% | ||
| Q1 25 | -276.6% | 44.2% | ||
| Q4 24 | -334.9% | -187.7% | ||
| Q3 24 | -278.2% | -114.5% | ||
| Q2 24 | -91.1% | — | ||
| Q1 24 | -110.6% | -160.9% |
净利率CRVORKDA
| Q4 25 | — | -148.3% | ||
| Q3 25 | — | 65.7% | ||
| Q2 25 | -356.1% | -306.4% | ||
| Q1 25 | -255.2% | 216.6% | ||
| Q4 24 | -310.2% | -334.5% | ||
| Q3 24 | -245.1% | -104.9% | ||
| Q2 24 | -70.4% | 81.2% | ||
| Q1 24 | -107.1% | -245.5% |
每股收益（稀释后）CRVORKDA
| Q4 25 | — | $-0.97 | ||
| Q3 25 | — | $0.62 | ||
| Q2 25 | — | $-3.26 | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | — | $-2.99 | ||
| Q3 24 | $-0.55 | $-1.18 | ||
| Q2 24 | — | $0.78 | ||
| Q1 24 | — | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.5M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $33.4M | $4.1M |
| 总资产 | $38.1M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRVORKDA
| Q4 25 | — | $4.6M | ||
| Q3 25 | — | $5.9M | ||
| Q2 25 | $33.5M | $4.4M | ||
| Q1 25 | $35.2M | $3.2M | ||
| Q4 24 | $38.9M | $4.2M | ||
| Q3 24 | $46.7M | $6.6M | ||
| Q2 24 | $45.1M | $8.1M | ||
| Q1 24 | $6.4M | $8.5M |
股东权益CRVORKDA
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | $33.4M | $4.5M | ||
| Q1 25 | $34.6M | $8.9M | ||
| Q4 24 | $39.2M | $6.2M | ||
| Q3 24 | $45.6M | $10.3M | ||
| Q2 24 | $50.0M | $11.7M | ||
| Q1 24 | $5.3M | $10.6M |
总资产CRVORKDA
| Q4 25 | — | $6.5M | ||
| Q3 25 | — | $8.6M | ||
| Q2 25 | $38.1M | $7.8M | ||
| Q1 25 | $38.6M | $13.0M | ||
| Q4 24 | $43.1M | $13.5M | ||
| Q3 24 | $48.9M | $15.2M | ||
| Q2 24 | $53.2M | $17.4M | ||
| Q1 24 | $8.0M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.5M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CRVORKDA
| Q4 25 | — | $-861.0K | ||
| Q3 25 | — | $-257.0K | ||
| Q2 25 | $-6.5M | $-2.0M | ||
| Q1 25 | $-3.9M | $-1.6M | ||
| Q4 24 | $-8.1M | $-2.2M | ||
| Q3 24 | $-4.9M | $-1.8M | ||
| Q2 24 | $-2.2M | $-2.5M | ||
| Q1 24 | $-1.4M | $-3.2M |
自由现金流CRVORKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-2.5M | ||
| Q1 24 | — | $-3.2M |
自由现金流率CRVORKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | — | -326.5% |
资本支出强度CRVORKDA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 1.3% |
现金转化率CRVORKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
